Form 4: Aligos Therapeutics CEO Granted Significant Stock Options

Aligos Therapeutics, Inc. President and CEO Lawrence Blatt was granted 179,800 stock options with an exercise price of $8.68, vesting monthly over four years.

Summary

• Lawrence Blatt, President and CEO of Aligos Therapeutics, Inc. (ALGS), was granted 179,800 stock options.
• The stock options have an exercise price of $8.68 per share.
• The vesting period for the options commences on July 16, 2025, with 1/48th of the total shares vesting in successive and equal monthly installments.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, contingent on Lawrence Blatt's continued service.
• The stock options are set to expire on July 16, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a positive step for aligning management incentives with shareholder interests, reflecting a standard compensation practice without indicating any immediate negative implications.

Positives

• The grant of 179,800 stock options to the President and CEO aligns management's long-term interests with shareholder value creation.
• The four-year vesting schedule encourages sustained commitment and performance from the executive leadership.

Future Outlook

The stock options granted to the President and CEO are structured to vest over four years, aligning future executive performance with long-term company growth and strategic objectives.

Management Comments

• The grant of stock options to President and CEO Lawrence Blatt reflects a standard executive compensation practice aimed at incentivizing long-term performance and aligning leadership interests with shareholder returns.

Industry Context

The grant of stock options to a key executive like the President and CEO is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize top talent, aligning their interests with the company's long-term success and shareholder value.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard compensation mechanism in the biotech industry, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for executive retention and performance alignment.
• An exercise price of $8.68, tied to the market price at the time of grant, is typical for incentive stock options, similar to grants observed at emerging biotech firms focused on research and development.

Stakeholder Impact

• Shareholders: Potential for increased alignment between executive performance and long-term shareholder value.
• Employees: May signal stability in leadership and a commitment to long-term company growth and success.

Next Steps

• Continued service of the Reporting Person through each vesting date to ensure full exercisability of the options.

Key Dates

Keywords

Aligos Therapeutics, ALGS, stock options, executive compensation, insider transaction, Form 4, Lawrence Blatt